These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34188043)

  • 1. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.
    Isermann T; Şener ÖÇ; Stender A; Klemke L; Winkler N; Neesse A; Li J; Wegwitz F; Moll UM; Schulz-Heddergott R
    Nat Commun; 2021 Jun; 12(1):4019. PubMed ID: 34188043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
    Isermann T; Schneider KL; Wegwitz F; De Oliveira T; Conradi LC; Volk V; Feuerhake F; Papke B; Stintzing S; Mundt B; Kühnel F; Moll UM; Schulz-Heddergott R
    bioRxiv; 2024 Feb; ():. PubMed ID: 38464125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.
    Shetzer Y; Kagan S; Koifman G; Sarig R; Kogan-Sakin I; Charni M; Kaufman T; Zapatka M; Molchadsky A; Rivlin N; Dinowitz N; Levin S; Landan G; Goldstein I; Goldfinger N; Pe'er D; Radlwimmer B; Lichter P; Rotter V; Aloni-Grinstein R
    Cell Death Differ; 2014 Sep; 21(9):1419-31. PubMed ID: 24832469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CKIα ablation highlights a critical role for p53 in invasiveness control.
    Elyada E; Pribluda A; Goldstein RE; Morgenstern Y; Brachya G; Cojocaru G; Snir-Alkalay I; Burstain I; Haffner-Krausz R; Jung S; Wiener Z; Alitalo K; Oren M; Pikarsky E; Ben-Neriah Y
    Nature; 2011 Feb; 470(7334):409-13. PubMed ID: 21331045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
    Li D; Yallowitz A; Ozog L; Marchenko N
    Cell Death Dis; 2014 Apr; 5(4):e1194. PubMed ID: 24763051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53.
    Ghaleb A; Yallowitz A; Marchenko N
    Commun Biol; 2019; 2():436. PubMed ID: 31799437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute HSF1 depletion induces cellular senescence through the MDM2-p53-p21 pathway in human diploid fibroblasts.
    Oda T; Sekimoto T; Kurashima K; Fujimoto M; Nakai A; Yamashita T
    J Cell Sci; 2018 May; 131(9):. PubMed ID: 29632240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1.
    Laudato S; Patil N; Abba ML; Leupold JH; Benner A; Gaiser T; Marx A; Allgayer H
    Int J Cancer; 2017 Nov; 141(9):1879-1890. PubMed ID: 28656629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
    Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
    J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear stress bodies: Interaction of its components in oncogenic regulation.
    Chatterjee M; Dass J FP; Sengupta S
    J Cell Biochem; 2019 Sep; 120(9):14700-14710. PubMed ID: 31090102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated bioinformatics and experiments reveal the roles and driving forces for HSF1 in colorectal cancer.
    Ren X; Zhang L; Ma X; Li J; Lu Z
    Bioengineered; 2022 Feb; 13(2):2536-2552. PubMed ID: 35006040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat Shock Factor 1 Epigenetically Stimulates Glutaminase-1-Dependent mTOR Activation to Promote Colorectal Carcinogenesis.
    Li J; Song P; Jiang T; Dai D; Wang H; Sun J; Zhu L; Xu W; Feng L; Shin VY; Morrison H; Wang X; Jin H
    Mol Ther; 2018 Jul; 26(7):1828-1839. PubMed ID: 29730197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
    Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
    Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis.
    Dai C; Santagata S; Tang Z; Shi J; Cao J; Kwon H; Bronson RT; Whitesell L; Lindquist S
    J Clin Invest; 2012 Oct; 122(10):3742-54. PubMed ID: 22945628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M; Quaas M; Nickel A; Engeland K
    Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
    Cuddihy AR; Jalali F; Coackley C; Bristow RG
    Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.